Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients
Status:
Recruiting
Trial end date:
2026-08-30
Target enrollment:
Participant gender:
Summary
This is an open-label, non-randomised, phase II, multi-centre clinical trial
26 patients will be enrolled in this trial to evaluate the major pathologic response in
patients with neoadjuvant treatment with Carboplatin Pemetrexed Bevacizumab plus Atezolizumab
in patients with non-small cell lung carcinoma locally advanced mutated in EGFR